We read with great interest the article entitled “Heparin Attenuates Histone-Mediated Cytotoxicity in Septic Acute Kidney Injury” by Wang et al. recently published in Frontiers in Medicine (1). In this article, the authors demonstrated that mice with cecal ligation and puncture- (CLP-) induced spetic acute kidney injury benefited from intraperitoneal heparin administration with improved survival, declined serum pro-inflammatory cytokines (namely tumor necrosis factor-a and interleukin-6) as well as kidney injury biomarkers (namely neutrophil gelatinase-associated lipocalin and kidney injury molecule-1), and decreased protein and mRNA expression levels of kidney apoptosis-related proteins (cleaved Caspase-3/Caspase-3 and Bax/Bcl-2) compared with those in the sepsis group at 6 h after CLP. Heparin may alleviate apoptosis and inflammation by neutralizing extracelluar histones and thus play a protective role against septic acute kidney injury.
Earlier literatures also showed that heparin and heparinoids could reduce histone-induced endothelial damage, inflammatory responses, coagulation activation, organ dysfunction and improve survival in septic mice (2–6). However, routine use of heparin in spetic patients is theoretically associated with high risk of fatal bleeding events as septic patients often develop disseminated intravascular coagulation (DIC) with excessive consumption of clotting factors and platelets (7, 8). Safety of direct heparin administration in patients with severe sepsis thus remains as a great concern. Unfortunately, the coagulation parameters as well as bleeding events in CLP-induced septic mice treated by 3 mg/kg of heparin were not available in the present work, preventing a more widespread clinical use of heparin as an anti-histone agent in patients with septic acute kidney injury.
Recently, non-anticoagulant heparins and small polyanions have been developed for histone neutralization to eliminate the bleeding concern of heparin use (6, 9). Wildhagen et al. demonstrated that an anti-thrombin affinity depleted heparin (AADH) could directly bind to histones with an apparent dissociation constant of 86 nM and effectively block histone-mediated cytotoxicity (6). Use of AADH in CLP-induced and lipopolysaccharide-induced septic mice significantly improved the survival rate and decreased neutrophil influx, intrapulmonary protein leakage and capillary-alveolar leakage with negligible prolongation of tail bleeding time (6). Likewise, O' Meara et al. developed non-anticoagulant O-sulfated small polyanions, derived from D-cellobiose, which interact electrostatically with histones and neutralize histone-mediated cytotoxicity, platelet aggregation and degranulation, and erythrocyte fragility (9). In vivo experiments further showed that these small polyanions could significantly inhibit histone-induced organ dysfunction, thrombocytopenia, anemia, and deep vein thrombosis as effective as heparin. However, at least 50 percent of mice treated by 6.25 mg/kg of heparin had to be euthanized due to bleeding in this study, highlighting the safety concern of heparin use in septic patients with DIC (9). Therefore, we recommend that further exploration should be performed to determine the potential advantage of non-anticoagulant heparins and other polyanions against unfractionated- or low-molecule-weight heparin in septic acute kidney injury in future.
Statements
Author contributions
YL and YW drafted the manuscript. All authors contributed to reviewing and revising the manuscript. All authors have given approval to the final version of the manuscript.
Funding
We acknowledge that this work is financially sponsored by the Science and Technology Achievement Transformation Fund of West China Hospital of Sichuan University (No. CGZH19006).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
WangZWangLCaoCJinHZhangYLiuYet al. Heparin attenuates histone-mediated cytotoxicity in septic acute kidney injury. Front. Med. (2020) 7: 586652. 10.3389/fmed.2020.586652
2.
ZhuCLiangYLiXChenNMaX. Unfractionated heparin attenuates histone-mediated cytotoxicity in vitro and prevents intestinal microcirculatory dysfunction in histone-infused rats. J Trauma Acute Care Surg. (2019) 87:614–22. 10.1097/ta.0000000000002387
3.
HogwoodJPitchfordSMulloyBPageCGrayE. Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS ONE. (2020) 15:e0233644. 10.1371/journal.pone.0233644
4.
LiLYuSFuSMaXLiX. Unfractionated heparin inhibits histone-mediated coagulation activation and thrombosis in mice. Thromb Res. (2020) 193:122–9. 10.1016/j.thromres.2020.06.007
5.
IbaTHashiguchiNNagaokaITabeYKadotaKSatoK. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intens Care Med Exp. (2015) 3:36. 10.1186/s40635-015-0072-z
6.
WildhagenKCAAGarciade Frutos PReutelingspergerCPSchrijverRAresteCOrtega-GomezAet al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. (2014) 123:1098–101. 10.1182/blood-2013-07-514984
7.
LiYPLiJMShiZQWangYLSongXWangLYet al. Anticoagulant chitosan-kappa-carrageenan composite hydrogel sorbent for simultaneous endotoxin and bacteria cleansing in septic blood. Carbohydr Polym. (2020) 243: 116470. 10.1016/j.carbpol.2020.116470
8.
AllamRKumarSVRDarisipudiMNAndersHJ. Extracellular histones in tissue injury and inflammation. J Mol Med. (2014) 92:465–72. 10.1007/s00109-014-1148-z
9.
O'MearaCHCouplandLAKordbachehFQuahBJCChangC-WDavisDASet al. Neutralizing the pathological effects of extracellular histones with small polyanions. Nat Commun. (2020) 11:6408. 10.1038/s41467-020-20231-y
Summary
Keywords
heparin, histone, coagulation, bleeding, septic acute kidney injury
Citation
Li Y, Wang Y, Jiang L, Song T and Su B (2021) Commentary: Heparin Attenuates Histone-Mediated Cytotoxicity in Septic Acute Kidney Injury. Front. Med. 8:647741. doi: 10.3389/fmed.2021.647741
Received
30 December 2020
Accepted
25 March 2021
Published
20 April 2021
Volume
8 - 2021
Edited by
Claudio Ronco, University of Padua, Italy
Reviewed by
Samy Hakroush, University of Göttingen, Germany
Updates
Copyright
© 2021 Li, Wang, Jiang, Song and Su.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Baihai Su subaihai@scu.edu.cn
This article was submitted to Nephrology, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.